A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea

Soon Min Lee, Jang Hoon Lee, Eun Song Song, Sung Jin Kim, Joon Hyung Kim, Rupert W Jakes, Raghavendra Devadiga, Moon Sung Park, Soon Min Lee, Jang Hoon Lee, Eun Song Song, Sung Jin Kim, Joon Hyung Kim, Rupert W Jakes, Raghavendra Devadiga, Moon Sung Park

Abstract

In 2010, Korea introduced 10-valent pneumococcal conjugate vaccine for children aged 6 weeks to 5 years against invasive disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and cross-reactive 19A. The aim of this 6-year real-world study of 646 healthy Korean children from 16 centers vaccinated in routine practice is to monitor vaccine safety, as per Ministry of Food and Drug Safety regulations. Around 50% had a past or existing medical condition, 19.3% an existing condition and 7.6% received concomitant medication). Total of 489 recorded adverse events (AEs) were reported in 274 infants; 86% were mild and the rest moderate, only three were reported as serious. Most AEs (97.8%) were not related to vaccination; one case of injection-site swelling and of fever was related, two cases of fever were probably related, five cases of fever and one case each of diarrhea and coughing were possibly related. None of the serious AEs were related to vaccination. Of 11 adverse drug reactions (ADRs) in 10 subjects, none were serious. Overall, 263 subjects (40.7%) received medication (mainly antibiotics or antipyretics) for the treatment of an AE, of which 6 subjects were treated for an ADR. There was no difference in the incidence of AEs according to age, sex or concomitant vaccination. Subjects with an existing medical condition had significantly more AEs than those without any conditions (p = 0.03), but no differences regarding ADRs. Four-dose vaccination with PHiD-CV appears to have a clinically-acceptable safety profile for Korean children. ClinicalTrials.gov identifier: NCT01248988.

Keywords: 10-valent pneumococcal conjugate vaccine; Korea; PHiD-CV; safety.

Figures

Figure 1.
Figure 1.
Duration of adverse events (days) (Total vaccinated cohort = 646). AE: adverse event

References

    1. Ghaffar F, Friedland IR, McCracken GH-J.. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J. 1999;18(7):638–646.
    1. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med. 2009;30(2):189–209. doi: 10.1055/s-0029-1202938.
    1. World Health Organization Immunization, vaccines and biologicals - pneumococcal disease. 2011. [accessed 2018 January 4]. .
    1. Centers for Disease Control and Prevention (CDC) Global Immunization - new and underused vaccines. Pneumococcus. 2017. [accessed 2017 July 22]. .
    1. World Health Organization Pneumococcal vaccines WHO position paper. 2012. [accessed]. .
    1. Weinberger DM, Trzcinski K, Lu YJ, Bogaert D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5(6):e1000476. doi: 10.1371/journal.ppat.1000706.
    1. Choi EH, Kim KH, Kim YJ, Kim JH, Park SE, Lee HJ, Eun BW, Jo DS, Choi KM, Hong YJ. Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea. Korean J Pediatr. 2011;54(4):146–151. doi: 10.3345/kjp.2011.54.4.146.
    1. European Medicines Agency 2017 Synflorix summary of product characteristics. 2017. [accessed 2017 July 22]. .
    1. European Medicines Agency Science medicines health. synflorix—procedural steps taken and scientific information after the authoristation. 2017. [accessed 2018 January 8]. .
    1. Domingues CM, Verani JR, Montenegro Renoiner EI, De Cunto Brandileone C, Flannery B, De Oliveira LH, Barberino Santos J, Cassio De Moraes J. the Brazilian pneumococcal conjugate vaccine effectiveness study group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2:464–471. doi: 10.1016/S2213-2600(14)70060-8.
    1. Synflorix Product Monograph, Canada 2017. [accessed 2017 July 22]. .
    1. Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in finnish children – a population-based study. PLoS One. 2015;10(3):e0120290. doi: 10.1371/journal.pone.0120290.
    1. Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–2689. doi: 10.1016/j.vaccine.2015.04.005.
    1. Haque A, Daniel S, Maxwell T, Boerstoel M. Postmarketing surveillance studies-an industry perspective on changing global requirements and implications. Clin Ther. 2017;39(4):675–685. doi: 10.1016/j.clinthera.2017.03.011.
    1. Ministry of Government Legislation. Postmarketing surveillance requirements (Articles 32 and 42) of the Pharmaceutical Affairs Act 2017. [accessed 2017 December 6]. .
    1. Synflorix Prescribing Information for Korea 2017. [accessed 2017 December 6]. .
    1. Plosker GL. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children. Paediatr Drugs. 2014;16(5):425–444. doi: 10.1007/s40272-014-0089-x.
    1. Huu TN, Toan NT, Tuan HM, Viet HL, Le Thanh Binh P, Yu TW, Shafi F, Habib A, Borys D. Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial. BMC Infect Dis. 2013;13:95. doi: 10.1186/1471-2334-13-95.
    1. Omeñaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V, Kafetzis D, Tsirka A, Athanassiadou F, Anagnostakou M, François N, et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011;128(2):e290–e298. doi: 10.1542/peds.2010-1184.
    1. Ministry of Food and Drug Safety. [Guideline for Re-examination of New Drugs] 2012. [accessed 2018 January 15]. .

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться